DMKPQ Dividend: DMK Pharmaceuticals Corp Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

DMKPQ Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	3	4	2	2	22	15
Revenue Growth (YoY)	200%	100%	0%	-91%	47%	15%
Cost of Revenue	4	6	6	6	15	9
Gross Profit	-1	-1	-4	-3	6	5
Selling, General & Admin	14	13	16	20	25	25
Research & Development	9	10	11	8	10	18
Operating Expenses	23	23	27	28	35	44
Other Non Operating Income (Expenses)	3	--	--	--	--	--
Pretax Income	-21	-26	-34	-35	-27	-39
Income Tax Expense	--	0	0	0	0	0
Net Income	-22	-26	-45	-49	-27	-39
Net Income Growth	-28.99%	-42%	-8%	81%	-31%	56%
Shares Outstanding (Diluted)	7.06	2.14	2.06	1.11	0.76	0.56
Shares Change (YoY)	229.99%	4%	86%	46%	36%	37%
EPS (Diluted)	-3.14	-12.37	-22.24	-44.49	-36.19	-69.66
EPS Growth	-79%	-44%	-50%	23%	-48%	12%
Free Cash Flow	-9	-26	-39	-21	-22	-36
Free Cash Flow Per Share	-1.27	-12.14	-18.93	-18.91	-28.94	-64.28
Gross Margin	-33.33%	-25%	-200%	-150%	27.27%	33.33%
Operating Margin	-833.33%	-625%	-1,600%	-1,550%	-131.81%	-260%
Profit Margin	-733.33%	-650%	-2,250%	-2,450%	-122.72%	-260%
Free Cash Flow Margin	-300%	-650%	-1,950%	-1,050%	-100%	-240%
EBITDA	-25	-24	-31	-28	-29	-36
EBITDA Margin	-833.33%	-600%	-1,550%	-1,400%	-131.81%	-240%
D&A For EBITDA	0	1	1	3	0	3
EBIT	-25	-25	-32	-31	-29	-39
EBIT Margin	-833.33%	-625%	-1,600%	-1,550%	-131.81%	-260%
Effective Tax Rate	--	0%	0%	0%	0%	0%